The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise (BALO)
The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise
In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.
The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.
Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Diepenbeek、比利时、3590
- Hasselt University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Obese group: BMI > 30 kg/m², sedentary (no regular physical activity last 6 months), insulin sensitive or insulin resistant
- Lean controls: BMI > 18.5 kg/m² and < 25 kg/m², regular physical activity, insulin sensitive
Exclusion Criteria:
- Regular glucose lowering medication or beta blockade medication
- Presence of chronical diseases
- Orthopedic or neurological problems
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
persons with obesity
|
adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
|
lean persons
|
adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Subcutaneous adipose tissue microdialysis
大体时间:week 1
|
abdominal subcutaneous adipose tissue microdialysis during rest and exercise; basal + under local alpha- and beta-blockade.
|
week 1
|
Atrial natriuretic peptide (ANP) Response
大体时间:week 1
|
measurement systemic ANP response (venous blood sampling)
|
week 1
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Central insulin sensitivity
大体时间:screening
|
Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g)
|
screening
|
Echocardiography
大体时间:Day 1
|
heart function by means of standard echocardiography
|
Day 1
|
Maximal oxygen uptake (ml/O2/kg/min)
大体时间:Day 1
|
measured using indirect calorimetry and an incremental bicycle protocol
|
Day 1
|
Anthropometry
大体时间:screening
|
body composition, measured using dual x-ray absorptiometry, height, weight, waist and hip circumference
|
screening
|
Abdominal subcutaneous adipose tissue biopsy
大体时间:week 1
|
biochemical, proteomics and morphological analyses
|
week 1
|
合作者和调查者
调查人员
- 首席研究员:Ellen Blaak, prof. dr.、Maastricht University
- 学习椅:Kenneth Verboven, drs、Hasselt University
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CME2014 /450
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.